MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-025-60598-4

Медицинская библиотека · Nature communications · 2025

Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.

Weiner Iddo, Kahan-Hanum Maya, Buchstab Nufar, Zelcbuch Lior, Navok Sharon, Sherman Irit, Nicenboim Julian, Axelrod Tim, Berko-Ashur Dikla, Olshina Maya, Mordoch Ron, Jablonska Jagoda, Gera-Inbar Tamar, Vainberg-Slutskin Ilya, Blumenfeld Britny, Sberro-Livnat Hila, Moses Ayelet, Nevenzel Hadas, Levy-Saar Inbal, Gold Jenia, Goldberg Meital, Tchernorudsky Nina, Ben-Yishay Noa, Cohen Tal, Kario Edith, Levovich Inesa, Safonov Roman, Tzur Yaron, Zarchin Yulia, Lev Vered, Elharar Yifat, Safyon-Gartman Einav, Gahali-Sass Inbar, Puttagunta Sailaja, Ussery Xilla, Vilchez Regis, Rappo Urania, Zak Naomi, Golembo Myriam, Cohen Ariel, Koff Jon, Kerem Eitan, Sorek Rotem, Bassan Merav

СтатьяРандомизированное исследованиеКлиническое исследование I фазыКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

Cystic fibrosis is a monogenetic disease complicated by recurrent bacterial lung infections that require chronic antibiotics. Pseudomonas aeruginosa is an increasingly antibiotic-resistant pathogen associated with cystic fibrosis morbidity and mortality. Here, we describe the development of a three-phage cocktail (BX004-A) designed to target a wide range of P. aeruginosa strains. We evaluated BX004-A in Part 1 of a first-in-human double-blind placebo-controlled phase 1b/2a clinical trial, which included nine adult cystic fibrosis patients chronically infected with P. aeruginosa (NCT05010577). BX004-A met the primary endpoints of safety and tolerability. Exploratory endpoints included pharmacokinetics and Pseudomonas aeruginosa sputum density reduction. Efficient phage delivery to the lower respiratory tract was observed, and a potential reduction in P. aeruginosa sputum burden was noted in the phage arm. However, due to the study's small sample size, definitive conclusions regarding efficacy are limited. These data pave the way toward further development of novel phage-based therapeutics in antibiotic-resistant pulmonary bacterial infections.

Для цитирования: Weiner Iddo, Kahan-Hanum Maya, Buchstab Nufar, Zelcbuch Lior, Navok Sharon, Sherman Irit, Nicenboim Julian, Axelrod Tim, Berko-Ashur Dikla, Olshina Maya, Mordoch Ron, Jablonska Jagoda, Gera-Inbar Tamar, Vainberg-Slutskin Ilya, Blumenfeld Britny, Sberro-Livnat Hila, Moses Ayelet, Nevenzel Hadas, Levy-Saar Inbal, Gold Jenia, Goldberg Meital, Tchernorudsky Nina, Ben-Yishay Noa, Cohen Tal, Kario Edith, Levovich Inesa, Safonov Roman, Tzur Yaron, Zarchin Yulia, Lev Vered, Elharar Yifat, Safyon-Gartman Einav, Gahali-Sass Inbar, Puttagunta Sailaja, Ussery Xilla, Vilchez Regis, Rappo Urania, Zak Naomi, Golembo Myriam, Cohen Ariel, Koff Jon, Kerem Eitan, Sorek Rotem, Bassan Merav. Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.. Nature communications. 2025. DOI: 10.1038/s41467-025-60598-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.